randomisation codes (AstraZeneca ltd)
90
Structured Review
AstraZeneca ltd
randomisation codes
Randomisation Codes, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randomisations/randomisation+codes/pmc03088470-86-1-14
Average 90 stars, based on 1 article reviews
Randomisation Codes, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randomisations/randomisation+codes/pmc03088470-86-1-14
Average 90 stars, based on 1 article reviews
randomisation codes - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction Article Snippet: The Article Title: Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke Article Snippet: The Sequencing:Article Title: Exploring the insulin secretory properties of the PGD 2 -GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients Article Snippet: If there is a need of a new randomisation code for subject replacement, the site is to contact the relevant representative at AstraZeneca to receive the correct randomisation number with the correct sequence to ensure the blinding of the study. .. If there is a need of a new Article Title: Gefitinib for advanced non‐small cell lung cancer Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote: "randomly assigned 1:1 according to a Article Title: Fulvestrant for hormone-sensitive metastatic breast cancer Article Snippet: Previous treatment with fulvestrant or any AI, previous endocrine therapy for breast cancer months previously, systemic chemotherapy for advanced breast cancer or as adjuvant therapy within the previous 4 weeks, extensive radiotherapy within previous 4 weeks, oestrogen-replacing treatment within 4 weeks of randomisation, abnormal hepatic function or lab or comorbid medical illnesses that would compromise safety or prevent interpretation of results Sponsored by AstraZeneca. .. Unspecified whether AstraZeneca was involved in the analyses, but unlikely that this would have affected the results of the study Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Explicitly described as randomised, double-blind, placebo-controlled study with study drugs being randomly allocated, although the method by which Selection:Article Title: Gefitinib for advanced non‐small cell lung cancer Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote: "randomly assigned 1:1 according to a Article Title: Fulvestrant for hormone-sensitive metastatic breast cancer Article Snippet: Previous treatment with fulvestrant or any AI, previous endocrine therapy for breast cancer months previously, systemic chemotherapy for advanced breast cancer or as adjuvant therapy within the previous 4 weeks, extensive radiotherapy within previous 4 weeks, oestrogen-replacing treatment within 4 weeks of randomisation, abnormal hepatic function or lab or comorbid medical illnesses that would compromise safety or prevent interpretation of results Sponsored by AstraZeneca. .. Unspecified whether AstraZeneca was involved in the analyses, but unlikely that this would have affected the results of the study Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Explicitly described as randomised, double-blind, placebo-controlled study with study drugs being randomly allocated, although the method by which |
